We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01600196
Recruitment Status : Completed
First Posted : May 16, 2012
Last Update Posted : May 16, 2012
Information provided by (Responsible Party):

May 13, 2012
May 16, 2012
May 16, 2012
January 2006
July 2009   (Final data collection date for primary outcome measure)
Survival time [ Time Frame: 5-years ]
Same as current
No Changes Posted
Number of Adverse Events [ Time Frame: 30 days ]
Number of adverse events, and number of patients who developed adverse event. Postoperative adverse events were graded based on the Clavien-Dindo classification.
Safety [ Time Frame: 30 days ]
Mobidity and mortality
Not Provided
Not Provided
Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus
Surgical Resection Versus Best Supportive Care for Resectable Hepatocellular Carcinoma Invading the First Branch of Portal Vein
The purpose of this study is to evaluate the long-term efficacy and safety of surgical resection compared with best supportive care in patients with resectable hepatocellular carcinoma (HCC) with portal venous thrombus (PVTT) in the first branch of portal vein.
Advances in surgical techniques have made it possible to remove all macroscopic tumors in more hepatocellular carcinoma (HCC) patients with portal venous thrombus (PVTT). However, the benefit of such surgery remains largely controversial. On one hand, many clinicians believe that surgical resection offers the only chance for long term survival. Many studies reported a median survival of 6-40 months after liver resection and thrombectomy, and some cases achieved long term survival.On the other hand, the strength of evidences arising from these studies was widely questioned because of their retrospective nature and study design. Most of them were single arm cohort study. A few studies used control groups consisted of patients with unresectable HCC and PVTT underwent transarterial chemoembolization. This led to obvious selection bias. Because patients with unresectable HCC and PVTT have a much poorer prognosis compared with resectable disease because of more widespread tumor focus and less residual liver, even if their baseline characters are comparable.
Phase 4
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Procedure: Liver resection plus Thrombectomy
Liver resection plus Thrombectomy
Other Name: Removal of all tumor tissue by surgery
  • Experimental: Resection arm
    Liver resection Plus Thrombectomy
    Intervention: Procedure: Liver resection plus Thrombectomy
  • No Intervention: Best support care arm
    Best supportive care
Le Treut YP, Hardwigsen J, Ananian P, Saïsse J, Grégoire E, Richa H, Campan P. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006 Jun;10(6):855-62.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
July 2011
July 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • The diagnosis of HCC was made according to AASLD guidelines
  • Main tumor ≥ 7 cm
  • Imaging confirmed the presence of PVTT in the first branches but not
  • Extend into the main trunk of portal vein
  • Eastern Co-operative Group performance
  • Resectable disease

Exclusion Criteria:

  • Child-Pugh class B or C liver cirrhosis
  • An American Society of Anesthesiologists (ASA) score ≥ 3
  • Extrahepatic metastasis
  • Patients had access to sorafenib.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Shi Ming, Sun Yat-sen University
Sun Yat-sen University
  • Guangzhou 8th People's Hospital
  • Kaiping Central Hospital
  • The 458 Hospital of Chinese People's Liberation Army
Principal Investigator: Ming Shi, MD. Sun Yat-sen University
Sun Yat-sen University
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP